Allergen, Individual-Drug Rifampicin antibiotic

The Allergen, Individual-Drug Rifampicin Antibiotic test is a targeted home-based allergy assessment designed to identify immune hypersensitivity to rifampicin. It evaluates drug-specific immune responses (such as rifampicin-specific IgE and/or cellular activation assays) from a blood sample to help determine whether a patient has an allergic predisposition to this antibiotic and to reduce the risk of adverse reactions during treatment.

This test is useful for patients with a prior suspected reaction to rifampicin or other rifamycin antibiotics, for clinicians planning tuberculosis or other rifampicin-containing regimens, and for individuals with multiple drug-allergy histories who require safer antibiotic selection. Testing is performed with at-home sample collection across Dubai and the UAE and results are reported to the ordering clinician to guide treatment decisions and minimise the risk of severe allergic events.

Limitations include that no single laboratory assay can guarantee absence of future hypersensitivity—results should be interpreted alongside clinical history, specialist input (allergist or infectious disease physician), and, where indicated, skin testing or supervised challenge. If positive or if clinical suspicion remains high despite a negative result, your treating physician in the UAE will advise on alternatives or referral for further immunoallergy evaluation.

• Rifampicin-specific IgE antibodies
• Total IgE (baseline)
• Basophil activation markers (CD63/CD203c) — if performed
• Drug-specific lymphocyte activation (LTT) — when indicated

• After a suspected allergic reaction to rifampicin (rash, hives, anaphylaxis)
• Before starting rifampicin in patients with prior multiple drug allergies
• When planning rifampicin therapy for TB and history of adverse drug reactions
• Recurrent unexplained fever or liver enzyme rise while on rifampicin
• To help differentiate allergic vs. non-allergic adverse reactions

• Identifies rifampicin-specific immune sensitisation to reduce reaction risk
• Supports safer antibiotic selection and treatment planning
• Convenient at-home sample collection across Dubai and the UAE
• Timely laboratory reporting to the treating clinician for rapid decisions
• Reduces likelihood of preventable hospital admissions from severe reactions

• At-home blood sample collection by a trained phlebotomist (venous sample)
• Inform provider of all current medications, recent antibiotics, and immunosuppressants
• Availability of a clinician to receive and interpret results in the UAE healthcare context
• Patient identification and valid prescription or physician referral required